DRUG USING STATUS IN PATIENTS WITH OSTEOPOROSIS AND PATHOLOGICAL FRACTURES

Introduction and Objective: Fractures are the primary complication associated with osteoporosis. Patients who are diagnosed with osteoporosis and have fractures due to the disease reported to be undermedicated and have poor compliance. Aim of the study is to evaluate the status of osteoporosis preventive medicine use of patients who have pathologic bone fractures due to osteoporosis. Method: Our cross sectional study includes patients who applied to our clinic in between August 2013-August 2015 and had been diagnosed with osteosteoporosisorosis+pathologic fracture. Patients’ status of osteoporosis-preventive (vitamin D, Calcium+vitamin D) and anti-osteosteoporosisorotic (bisphosphonates, calcitonin, raloxifene, teriparatide, selective estrogen receptor modulators, strontium ranelate, denosumab) therapy use before the diagnosis and once every 3 months after the diagnosis was recorded. Results and Conclusion: The mean age of total 210 participants was 66.7±12.9 years. 80%of the participants was female and 20% was male. 65.7% of the patients didn’t have any kind of osteoporosis preventive medicine before the diagnosis of fracture. 26.5% of the patients didn’t take medicine after fracture. After a year; this percentage increased to 51%. The percentage of patients who had anti-osteoporotic therapy within the first three months after fracture, decreased to 79.4% by the end of second three months and 57.1% after a year. We concluded that use of medicine after osteosteoporotic fracture was insufficient and patient compliance was poor. So a novel method that will make treatment more effective needs to be considered.